Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Outlook for Pediatric Drug Development Looks Promising, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Nov 15, 2016) - Resources dedicated to creating medicines to meet the unique needs of children have grown steadily since legislation guiding pediatric drug...
September 20, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Diabetes Drug Development Is Riskier Compared to All Drug Development, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Sep 20, 2016) - Whereas scores of new diabetes and non-diabetes endocrine drugs have been launched since the mid-1990s, and the demand for new therapies continues to...
July 14, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Global Regenerative Medicine Market Is Poised for Strong Growth, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Jul 14, 2016) - A strong development pipeline for regenerative medicine (RM) therapies aimed at treating a broad range of unmet medical needs signals rapid growth in...
May 10, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - May 10, 2016) - Rising drug prices in the United States will lead payers and pharmaceutical benefit managers (PBMs) to increase the number of drugs ineligible for...
March 10, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Tufts Center for the Study of Drug Development Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published

BOSTON, MA--(Marketwired - Mar 10, 2016) - The most recent analysis by the Tufts Center for the Study of Drug Development of the average cost to develop and gain marketing approval for a new drug...
March 08, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Promise of Immuno-Oncology Therapies Is Boosting R&D Funding and Alliances, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Mar 8, 2016) - Investments in research and development for new immuno-oncology (I/O) drugs, along with dramatic improvements in complete response rates in trials for new...
January 26, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

New Approaches to Patient Recruitment and Retention Anticipate Structural Change in the Clinical Research Enterprise, Tufts Center for the Study of Drug Development Reports

BOSTON, MA--(Marketwired - Jan 26, 2016) - Responding to strong and growing pressures to accelerate the pace at which new medicines are launched, drug developers are innovating clinical study...
January 14, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Protocol Amendments Improve Elements of Clinical Trial Feasibility, But at High Economic and Cycle Time Cost, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Jan 14, 2016) - Research sponsors implement at least one substantial global amendment for nearly 60% of all clinical trial protocols, substantially reducing the number of...
January 07, 2016 09:00 ET | Source: Tufts Center for the Study of Drug Development

Drug Developers Are Working to Boost R&D Productivity, But Need to do More to Achieve Large-Scale Improvements, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Jan 7, 2016) - While drug developers during the coming year will continue their efforts to meet the growing demand for innovative new medicines, they must also...
November 03, 2015 09:00 ET | Source: Tufts Center for the Study of Drug Development

Nearly All Later Entrants to Drug Classes Were in Clinical Testing or Regulatory Review Before First-in-Class Approval, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Nov 3, 2015) - Nearly all later entrants to drug classes had begun clinical testing or were in regulatory review in the United States before the first drug within a...